A Bayesian Stopping Rule for Sequential Monitoring of Serious Adverse Events

被引:0
|
作者
Kosuke Kashiwabara
Yutaka Matsuyama
Yasuo Ohashi
机构
[1] University of Tokyo,Department of Biostatistics, School of Public Health, Graduate School of Medicine
关键词
Bayesian; clinical trials; interim monitoring; sequential monitoring; serious adverse events; stopping rule;
D O I
暂无
中图分类号
学科分类号
摘要
In an ongoing clinical trial, there will always be a risk for unanticipated critical safety problems, such as excessive occurrence of serious adverse events. When such a problem arises, the trial administrators must conduct an immediate evaluation to determine whether the trial should be terminated to protect patients. This decision is complicated but may be aided by statistical stopping rules. Sequential stopping rules are appropriate for immediate decisions, but frequentist approaches may not be useful because the unknown truncated end of the trial makes it impossible to define type I errors. Thus, a Bayesian stopping rule is proposed that is based on the posterior distribution with an informative prior distribution, and a guideline to construct this stopping rule is presented. Some operating characteristics are evaluated and compared with those of the modified sequential probability ratio test (SPRT), the maximized SPRT, and Pocock’s test. The proposed method has flexibility for construction and could provide a more desirable performance than the other compared methods.
引用
收藏
页码:444 / 452
页数:8
相关论文
共 50 条
  • [1] A Bayesian Stopping Rule for Sequential Monitoring of Serious Adverse Events
    Kashiwabara, Kosuke
    Matsuyama, Yutaka
    Ohashi, Yasuo
    [J]. THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2014, 48 (04) : 444 - 452
  • [2] Early Stopping Rules in Clinical Trials Based on Sequential Monitoring of Serious Adverse Events
    Kramar, A.
    Bascoul-Mollevi, C.
    [J]. MEDICAL DECISION MAKING, 2009, 29 (03) : 343 - 350
  • [3] Quantitative Methods for Safety Monitoring of Rare Serious Adverse Events
    Duke S.P.
    Kleoudis C.
    Polinkovsky M.
    Bennett D.
    Hill D.
    Lewis E.
    [J]. Pharmaceutical Medicine, 2017, 31 (2) : 113 - 118
  • [4] Bayesian stopping rule for normal distribution
    Wang, FK
    Keats, JB
    Leu, BY
    [J]. INTERNATIONAL JOURNAL OF INDUSTRIAL ENGINEERING-THEORY APPLICATIONS AND PRACTICE, 2004, 11 (01): : 74 - 81
  • [5] Bayesian stopping rule for normal distribution
    Wang, F.K.
    Keats, J. Bert
    Leu, B.Y.
    [J]. Int J Ind Eng Theory Appl Pract, 1600, 1 (74-81):
  • [6] Remimazolam and serious adverse events
    Kempenaers, Sander
    Hansen, Tom G.
    van de Velde, Marc
    [J]. EUROPEAN JOURNAL OF ANAESTHESIOLOGY, 2023, 40 (11) : 841 - 853
  • [7] Bayesian optimum stopping rule for software release
    Kumar, Chakraborty Ashis
    Basak, Gopal Krishna
    Das, Suchismita
    [J]. OPSEARCH, 2019, 56 (01) : 242 - 260
  • [8] Bayesian optimum stopping rule for software release
    Ashis Kumar Chakraborty
    Gopal Krishna Basak
    Suchismita Das
    [J]. OPSEARCH, 2019, 56 : 242 - 260
  • [9] Distribution of the stopping time in Bayesian sequential sampling
    Pham-Gia, T
    [J]. AUSTRALIAN & NEW ZEALAND JOURNAL OF STATISTICS, 1998, 40 (02) : 221 - 227